22:45 , Jun 20, 2018 |  BC Extra  |  Company News

Management tracks: Sanofi, NantKwest

Sanofi (Euronext:SAN; NYSE:SNY) hired Jean-Baptiste Chasseloup de Chatillon as EVP and CFO, effective Oct. 1. He was CFO and EVP at automotive company PSA Group (Euronext:UG). Natural killer cell company NantKwest Inc. (NASDAQ:NK) said Chief Accounting...
19:10 , May 4, 2018 |  BC Week In Review  |  Company News

Horizon Discovery rejects bid from Abcam

On May 2, gene editing company Horizon Discovery Group plc (LSE:HZD) rejected an April 19 proposal from Abcam plc (LSE:ABC) to acquire the company for 181p per share, or about £270 million ($371 million). The...
18:16 , Oct 26, 2017 |  BC Innovations  |  Emerging Company Profile

Taking RNA epigenetics by Storm

Storm Therapeutics Ltd. is the first company to come out of the budding field of RNA epigenetics, and is targeting RNA-modifying enzymes for cancer. CEO Keith Blundy told BioCentury RNA-modifying enzymes fit into the landscape of...
22:53 , May 26, 2017 |  BioCentury  |  Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big caps...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Company News

Horizon Discovery, Abcam deal

Horizon granted Abcam exclusive rights to more than 1,800 diploid and haploid cell line models developed using Horizon’s X-MAN technology, which Abcam will use to validate the function of its antibodies. Horizon will also develop...
07:00 , Jul 23, 2015 |  BC Innovations  |  Tools & Techniques

The price of a gold standard

While a new protocol for validating antibodies from the Structural Genomics Consortium goes part way toward addressing one of the biggest sources of irreproducibility in academic research, stakeholders agree a widespread solution will likely require...
01:41 , Jul 1, 2015 |  BC Extra  |  Company News

Management tracks

Merck & Co. Inc. (NYSE:MRK) and the Sanofi Pasteur S.A. vaccines unit of Sanofi (Euronext:SAN; NYSE:SNY) hired David Khougazian as president of their Sanofi Pasteur MSD joint venture. Khougazian was Sanofi's CEO chief of staff....
08:00 , Feb 2, 2015 |  BC Week In Review  |  Company News

Firefly BioWorks, Abcam deal

Research tool company Abcam acquired microRNA assay company Firefly for L18.5 million ($27.8 million) in cash on a debt- and cash-free basis. Firefly BioWorks Inc., Cambridge, Mass.   Abcam plc (LSE:ABC), Cambridge, U.K.   Business: Supply/Service   ...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Company News

Abcam management update

Abcam plc (LSE:ABC), Cambridge, U.K.   Business: Antibodies   Transitioned: Alan Hirzel to CEO from CMO, while remaining a director; he succeeds Jonathan Milner, who becomes deputy chairman   ...